(A1)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

162162

(43) International Publication Date
22 August 2002 (22.08.2002)

PCT

(10) International Publication Number
WO 02/064126 A3

(51) International Patent Classification[7]: A61K 31/4439, A61P 25/00, 13/10

(21) International Application Number: PCT/US02/05501

(22) International Filing Date: 14 February 2002 (14.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/268,846 15 February 2001 (15.02.2001) US
0119435.6 9 August 2001 (09.08.2001) GB

(71) Applicant *(for all designated States except US)*: **AVENTIS PHARMACEUTICALS INC.** [US/US]; 300 Somerset Corporate Boulevard, Bridgewater, NJ 08807-2854 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SMITH, Craig, P.** [US/US]; 531 Brookside Lane, Hillsborough, NJ 08844 (US). **RATHBONE, Michel, P.** [CA/CA]; 15 Ricardo Court, Hamilton, Ontario L8N 3Z5 (CA). **PETTY, Margaret** [US/US]; 64 Bradley Lane, Bridgewater, NJ 08807 (US). **RAMPE, David** [US/US]; 36 Prospect Street, Bernardsville, NJ 07924 (US).

(74) Agents: **KURYS, Barbara, E.** et al.; Route 202-206, P.O. Box 6800, Bridgewater, NJ 08807-0800 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv)) for US only*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
20 February 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

G00002

WO 02/064126 A3

(54) Title: METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS

(57) Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.